Morningstar - Peugeot SA (UG) Peugeot Reports Solid 3Q Revenue Growth; EUR 11 FVE Unchanged

Report

Morningstar

Richard Hilgert

EUR 101.80 For Business Accounts Only

Peugeot Reports Solid 3Q Revenue Growth; EUR 11 FVE Unchanged

No-moat-rated Peugeot reported a 12% increase in third-quarter 2017 auto division revenue, which excludes Opel/Vauxhall and Faurecia. However, auto division revenue assuming constant currency would have been up by 14%. The result was much stronger than we anticipated. We forecast full-year revenue to increase 5%. Year to date, including the strong third quarter, auto division revenue has increased 6% versus the same nine-month period last year. Even so, we think the market has gotten ahead of it...

25/10/2017 13 EN

Underlying

Peugeot SA

Peugeot is an automobile manufacturer (cars and light commercial vehicles), supported by two brands: Peugeot and Citroen. Co.'s activities are divided into four main segments: Automobile (Co. designs, manufactures and markets passenger cars and light commercial vehicles under Peugeot and Citroen brands), Finance (Co. provides retail and wholesale financing to customers and dealer networks), Automotive equipment (Co. produces Interior Systems, Automotive Seating, Automotive Exteriors and Emissions Control Technologies) and Other businesses (Co. produces scooters).

See profile

FR0000121501 France

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Richard Hilgert

Other Reports on these Companies

MarketLine

Fiat Chrysler Automobiles N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances

Summary Marketline's Fiat Chrysler Automobiles N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Fiat Chrysler Automobiles N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic grow...

EUR 300.65

January 29, 2025 January 29, 2025 1 EN

Degroof Petercam

Peugeot Invest - FY23: High discount but potential for better times

• FY23 NAV at EUR 237.7 p/s, up 21.1%, in line with our estimate. Proposed dividend of EUR 3.25 p/s, up 14% YoY, and above our estimate. The real estate portfolio struggled with full impairment• We estimate today's NAV to be EUR 283.4 p/s, implying a discount of 58%. That is incredibly high and among the highest in the sector. We look forward to the announcement of the new CEO in hopes that he/her will bring change to the strategy and portfolio composition. This could become a major trigger for the discount• In the meantime, we reiterate our Hold rating.

March 21, 2024 March 21, 2024 1 EN

Degroof Petercam

Peugeot Invest - Signa declares insolvency

• Signa, one of the largest private real estate companies in Europe, declared insolvency on Wednesday evening• Peugeot Invest has invested about EUR 306m in Signa vehicles or about 5% of the NAV. This is now at risk of being wiped out following a much-needed restructuring. We took a full impairment for EUR 12 p/s• We estimate the adjusted NAV at EUR 206.8 p/s implying a discount of 49%. We lower our TP to EUR 109 (vs. EUR 121 before). Hold reiterated

November 30, 2023 November 30, 2023 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Peugeot Reports Solid 3Q Revenue Growth; EUR 11 FVE Unchanged

Fiat Chrysler Automobiles N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances

Peugeot Invest - FY23: High discount but potential for better times

Peugeot Invest - Signa declares insolvency

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe